Rein Therapeutics Statistics
Total Valuation
RNTX has a market cap or net worth of $90.36 million. The enterprise value is $90.84 million.
Important Dates
The next estimated earnings date is Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RNTX has 93.04 million shares outstanding. The number of shares has increased by 29.11% in one year.
| Current Share Class | 93.04M |
| Shares Outstanding | 93.04M |
| Shares Change (YoY) | +29.11% |
| Shares Change (QoQ) | +3.72% |
| Owned by Insiders (%) | 6.16% |
| Owned by Institutions (%) | 13.74% |
| Float | 77.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 7.80 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.40, with a Debt / Equity ratio of 0.42.
| Current Ratio | 0.40 |
| Quick Ratio | 0.33 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -163.36% and return on invested capital (ROIC) is -40.58%.
| Return on Equity (ROE) | -163.36% |
| Return on Assets (ROA) | -32.10% |
| Return on Invested Capital (ROIC) | -40.58% |
| Return on Capital Employed (ROCE) | -170.36% |
| Weighted Average Cost of Capital (WACC) | 11.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$5.02M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -712,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.94% in the last 52 weeks. The beta is 1.35, so RNTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.35 |
| 52-Week Price Change | -36.94% |
| 50-Day Moving Average | 1.16 |
| 200-Day Moving Average | 1.27 |
| Relative Strength Index (RSI) | 46.55 |
| Average Volume (20 Days) | 629,071 |
Short Selling Information
The latest short interest is 312,225, so 0.34% of the outstanding shares have been sold short.
| Short Interest | 312,225 |
| Short Previous Month | 387,486 |
| Short % of Shares Out | 0.34% |
| Short % of Float | 0.40% |
| Short Ratio (days to cover) | 0.61 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -21.55M |
| Pretax Income | -50.92M |
| Net Income | -50.21M |
| EBITDA | -21.57M |
| EBIT | -21.55M |
| Earnings Per Share (EPS) | -$1.82 |
Full Income StatementBalance Sheet
The company has $4.45 million in cash and $4.92 million in debt, giving a net cash position of -$478,000 or -$0.01 per share.
| Cash & Cash Equivalents | 4.45M |
| Total Debt | 4.92M |
| Net Cash | -478,000 |
| Net Cash Per Share | -$0.01 |
| Equity (Book Value) | 11.59M |
| Book Value Per Share | -1.19 |
| Working Capital | -8.18M |
Full Balance SheetCash Flow
| Operating Cash Flow | -16.61M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | -14,500 |
| Net Borrowing | 4.30M |
| Free Cash Flow | -16.61M |
| FCF Per Share | -$0.18 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |